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Minutes of the Virtual Meeting 
The U.S. Department of Health and Human Services (HHS) and the Centers for Disease 
Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD and TB 
Prevention (NCHHSTP), Division of Tuberculosis Elimination (DTBE) convened a virtual 
meeting of the Advisory Council for the Elimination of Tuberculosis (ACET) on March 4, 2014. 
ACET is chartered to provide advice to the Secretary of HHS and the Director of CDC regarding 
the elimination of tuberculosis (TB); make recommendations regarding policies, strategies, 
objectives and priorities; address the development and application of new technologies; provide 
guidance on CDC’s TB Prevention Research portfolio and program priorities; and review the 
extent to which progress has been made toward eliminating TB.  
Opening Session 
Hazel Dean, ScD, MPH 
Deputy Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
ACET Designated Federal Officer 
Dr. Dean conducted a roll call to determine the ACET voting members, ex-officio members and 
liaison representatives who were attending the virtual meeting.  She announced that ACET 
meetings are open to the public and all comments made during the proceedings are a matter of 
public record. 
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Dr. Dean informed the ACET voting members of their individual responsibility to identify 
potential conflicts of interest and recuse themselves from voting or participating in these 
matters.  During the roll call, she asked the ACET voting members to publicly disclose their 
individual and/or institutional conflicts of interest for the record. 
• Jennifer Cochran, MPH:  Recipient of funding from the CDC TB Cooperative Agreement 
(CoAg) 
Dr. Dean announced that the voting members and ex-officio members constituted a quorum for 
ACET to conduct its business on March 4, 2014 (Attachment 1: Participants’ Directory).  She 
called the proceedings to order at 11:01 a.m. EST and welcomed the participants to the virtual 
ACET meeting.  She reviewed the instructions for the ACET members to be recognized by the 
Chair and pose questions or make comments remotely. 
Dr. Dean concluded her opening remarks by describing both temporary and permanent changes 
to ACET’s membership. 
• The term of Mr. Shannon Jones, the former ACET Chair, has ended.  Ms. Barbara Cole, 
a TB Controller at Riverside County (California) Department of Public Health, was 
welcomed as the new ACET Chair. 
• Mr. José Velasco, Executive Director of the U.S. Section of the U.S. Mexico Border 
Health Commission, was named as the permanent alternate ex-officio member for this 
agency in the event of Dr. Bruce San Filippo’s absence. 
• Ms. Marla Clifton would serve as the ex-officio member for the U.S. Department of 
Veteran Affairs during the current meeting in the absence of Dr. Gary Roselle. 
• Dr. YaDiul Mukadi would serve as the ex-officio member for the U.S. Agency for 
International Development (USAID) during the current meeting in the absence of Dr. 
Amy Bloom. 
• Efforts are underway to replace Ms. Tiffany Moore, the former ex-officio member for the 
U.S. Marshals Service. 
• The terms of four ACET members would expire in June 2014:  Drs. Eric Brenner, Marcos 
Burgos, Jane Carter and Gail Cassell.  The outgoing members were commended for 
their excellent service and commitment to TB elimination efforts for ACET, CDC and the 
nation.  On January 14, 2014, DTBE submitted nomination packages to the CDC 
Committee Management Office to replace the four outgoing members. 
Barbara Cole, RN, MSN, PHN 
TB Controller 
Riverside County (California) Department of Public Health 
ACET Chair 
Ms. Cole joined Dr. Dean in welcoming the participants to the virtual ACET meeting.  She noted 
her privilege and honor in serving as the new ACET Chair.  She concluded the opening session 
by reviewing the agenda items and emphasizing the importance of the members participating in 
all sessions of the virtual meeting to ensure that ACET maintains its quorum. 
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NCHHSTP Director’s Report 
Hazel Dean, ScD, MPH 
Deputy Director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
Centers for Disease Control and Prevention 
ACET Designated Federal Officer 
Dr. Dean covered the following topics in the NCHHSTP Director’s report to ACET.  At the 
agency level, CDC’s FY2014 appropriation of ~$6.8 billion includes $30 million for the 
establishment of an Advanced Detection Molecular Program.  CDC will use these funds to more 
accurately and rapidly diagnose infectious diseases; investigate and control outbreaks, including 
TB outbreaks; better understand transmission patterns; determine antimicrobial resistance; and 
develop and target prevention measures, including vaccines. 
CDC published its second U.S. Health Disparities and Inequalities Report in 2013 that 
highlighted differences in mortality and disease risks for multiple conditions related to behaviors, 
access to health care and social determinants of health.  In addition to covering HIV infection 
and 18 other topics that were featured in the first report, the second report also included TB and 
nine other new topics.  The second report noted that compared to whites, TB rates in 2010 were 
~25 times higher among Asians/Pacific Islanders, ~8 times higher among African Americans, 
and ~7 times higher among Hispanics. 
CDC published its 2013 Prevention Status Reports that described the status of public health 
policies and practices in all 50 states and the District of Columbia to prevent or reduce important 
public health problems.  The priority health topics covered in the report included excessive 
alcohol use, food safety, healthcare-associated infections, heart disease and stroke, HIV, motor 
vehicle injuries, nutrition, physical activity and obesity, prescription drug overdose, teen 
pregnancy and tobacco use. 
CDC published its Antibiotic Resistance Threats in the United States Report in October 2013.  
The report noted that of >2 million persons who are infected with an antibiotic-resistant infection 
each year, 23,000 die.  The report classified antibiotic-resistant threats into one of three 
categories:  “urgent,” “serious” or “concerning.”  Drug-resistant gonorrhea was classified as an 
“urgent” threat, while drug-resistant TB was classified as a “serious” threat.”  CDC’s three 2013 
reports are available for review on the CDC.gov website. 
At the National Center level, NCHHSTP is responding to changes in its leadership.  Dr. Kenneth 
Castro, Director of DTBE, is serving as the Acting Director of the Division of HIV/AIDS 
Prevention (DHAP) until a permanent replacement is appointed.  Instead of returning to his 
position, however, Dr. Castro has announced his plans to retire later in 2014. 
Dr. Dean asked the participants to join her in congratulating Dr. Castro on his long and 
distinguished public health career as an Epidemic Intelligence Officer with the CDC HIV/AIDS 
Program beginning in 1983, a Commissioned Corps Officer in the U.S. Public Health Service 
(USPHS), and the Director of DTBE for the past 20 years.  The ACET members were 
encouraged to inform their colleagues and peers of the March 14, 2014 deadline to submit 
applications for the position of the DHAP Director.  
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Dr. Castro’s upcoming retirement will create a vacancy in the position of the DTBE Director, but 
Dr. Philip LoBue is serving as the Acting Director until a permanent replacement is appointed.  
CDC broadly announced this position through multiple venues, including direct communications 
with its TB partners, TB and public health newsletters, the CDC.gov website and CDC’s social 
media platforms.  After the eligibility certificates of potential candidates are validated over the 
next few weeks, the CDC Search Committee will conduct interviews in April-May 2014. 
NCHHSTP released its expanded “Atlas” with local, county-level epidemiologic data for HIV and 
STDs to enhance capacity to identify areas of the United States with the greatest disease 
burden.  NCHHSTP published two supplements to Public Health Reports:  “Applying Social 
Determinants of Health to Public Health Practice” and “Program Collaboration and Service 
Integration” (PCSI).  The NCHHSTP Office of Health Equity celebrated its 10th anniversary on 
November 7, 2013 and featured a keynote presentation, “From Theory to Action: Applying 
Social Determinants of Health to Public Health Practice.” 
At the division level, the DTBE budget increased from the FY2013 operating level of ~$133 
million to the FY2014 Omnibus appropriation of $135 million.  DTBE issued guidance on a new 
anti-TB drug in 2013.  Bedaquiline is the first new drug that the U.S. Food and Drug 
Administration (FDA) has specifically approved for TB since 1968.  Bedaquiline also serves as 
an additional tool against multidrug-resistant TB (MDR-TB). 
DTBE is leading a post-marketing surveillance study to determine whether a three-month, once-
weekly isoniazid/rifapentine regimen for latent TB infection (LTBI) treatment can be successfully 
adopted for TB prevention.  DTBE is collaborating with 22 external partners in this effort and has 
enrolled 1,500 patients in the study to date.  DTBE recently released a mobile application for 
healthcare providers (HCPs), “Latent TB Infection: Guide for Diagnosis and Treatment.”  The 
application can be downloaded from the AppStore and Google Play websites. 
DHAP released interim guidance on the use of pre-exposure prophylaxis (PrEP) for injection 
drug users based on study results that showed PrEP prevented HIV in this population.  DHAP 
published the 2013 National HIV Prevention Progress Report that showed 62% of targets 
established for national HIV prevention efforts were met or exceeded. 
DHAP issued its first Rapid Feedback Report for grantees of the “Young Men Who Have Sex 
with Men and Transgender Persons of Color” Funding Opportunity Announcement (FOA).  The 
report compares progress and performances across the entire FOA and provides each grantee 
with individual feedback.  DHAP launched “Reasons/Razones” as the first national bilingual 
campaign to encourage HIV testing among Latino gay/bisexual men as well as the second 
phase of the “Let’s Stop HIV Together” campaign in English and Spanish. 
The Division of Adolescent and School Health (DASH) is now being led by its new Director, Dr. 
Stephanie Zaza, who has had a distinguished public health career at CDC since 1991.  DASH 
awarded funds for a new five-year school health FOA, “Promoting Adolescent Health Through 
School-Based HIV/STD Prevention and School-Based Surveillance.”  The funding amounts 
were based on the highest HIV burden of states and the HIV/STD burden, poverty level and 
number of students of local school districts. 
DASH released the updated “Health Education Curriculum Analysis Tool” to help school districts 
and schools analyze and ensure that their health education curricula follow federal guidelines.  
DASH released results of the “2012 School Health Policies and Practices Study.”  The national 
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study assesses school health policies and practices.  The study reported a decrease in the 
percentage of school districts that require elementary schools to teach HIV prevention from 59% 
in 2000 to 40% in 2012. 
The Division of Viral Hepatitis (DVH) published guidelines that recommended hepatitis C virus 
(HCV) testing of persons born between 1945 and 1965 due to increased risk of infection in this 
population.  DVH published the first HCV treatment cascade in the New England Journal of 
Medicine that reported <10% of infected persons have been treated and cured.  DVH led CDC’s 
investigation that successfully identified pomegranate seeds from Turkey as the source of a 
multi-state outbreak of hepatitis A.  DVH launched the “Know More Hepatitis B” Campaign in 
June 2013.  The national multimedia campaign is targeted to Asians/Pacific Islanders and was 
released in English, Chinese, Vietnamese and Korean. 
The Division of STD Prevention (DSTDP) began awarding funds in January 2014 under its new 
FOA, “Improving Sexually Transmitted Disease Programs Through Assessment, Assurance, 
Policy Development and Prevention Strategies.”  The new FOA will provide programs with 
greater flexibility to target resources to areas based on local needs. 
DTSTDP completed a clinical trial that found two new antibiotic regimens successfully treated 
gonorrhea infections.  DSTDP published a study in June 2013 that reported a 56% decrease in 
vaccine-type human papillomavirus (HPV) prevalence among female teens 14-19 years of age 
since the introduction of HPV vaccine in 2006.  DSTDP and its partners released an application 
for the new STD Treatment Guidelines that are available to clinicians and other HCPs.  The 
application can be downloaded from the AppStore and Google Play websites. 
The NCHHSTP Director’s report resulted in ACET making comments and suggestions in two 
areas.  First, CDC should create a repository or a specific website with links to all of its mobile 
applications.  A “one-stop” resource for these applications would be extremely helpful to state 
and local health departments. 
Second, ACET requested more details on the criteria that CDC used to classify and define 
antibiotic-resistant infections as an “urgent,” “serious” or “concerning” threat.  Several members 
expressed concern that CDC’s 2013 report, Antibiotic Resistance Threats in the United States, 
classified gonorrhea as an “urgent” threat and drug-resistant TB as a “serious” threat.” 
The ACET members noted that because drug-resistant TB is a global problem, CDC’s lower 
classification of “serious” rather than “urgent” could have an adverse public health impact.  The 
ACET members also pointed out although the TB case count is much lower than case counts of 
gonorrhea or other infectious diseases, airborne transmission of TB is a much greater threat to 
the public than sexual transmission of gonorrhea. 
DTBE Director’s Report 
Philip LoBue, MD, FACP, FCCP 
Acting Director, Division of Tuberculosis Elimination 
Centers for Disease Control and Prevention 
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Dr. LoBue explained that the DTBE Director’s report to ACET would focus on one specific topic.  
DTBE initiated a strategic alignment process of its TB priorities, activities, staffing and budget 
after the 2013 budget sequestration.  DTBE realized that reactive across-the-board funding cuts 
would be unsustainable and eventually would lead to all major TB activities and programs (e.g., 
Regional Training and Medical Consultation Centers (RTMCCs), Tuberculosis Epidemiologic 
Studies Consortium, and Tuberculosis Trials Consortium) being under-funded and unable to 
meet goals. 
DTBE agreed that the preferred approach would be to make strategic rather than across-the-
board cuts to preserve higher priority activities and eliminate lower priority activities if the budget 
sequestration continued in the future.  DTBE also recognized that growing staff costs could not 
be sustained over time.  DTBE further agreed that its existing vision, mission, priorities, core 
activities and indicators were well defined and did not need to be revisited or modified. 
DTBE’s initial effort in its strategic alignment process was to determine the best distribution of 
funding based on three areas described in the 1989 plan to eliminate TB:  make optimal use of 
existing tools, develop new tools, and translate new tools into practice.  However, DTBE’s 
review and initial discussions showed that these three activities were difficult to clearly define, 
make sharp distinctions and implement in the field.  Most notably, the three activities overlap 
and have varying definitions.  DTBE eventually concluded that additional emphasis and funding 
would be needed to support the translation of new tools into actual practice. 
DTBE convened and charged a group of mid-level leaders (i.e., the “Think Tank”) with offering 
creative and concrete recommendations for cross-cutting activities to implement DTBE’s 
mission over the next 3-5 years in the face of changes in TB epidemiology and limited resources 
for TB prevention and control.  The Think Tank proposed nine topics to be considered for 
inclusion in the DTBE strategic alignment plan:  funding of state and local TB programs, 
outbreaks and genotyping, surveillance, global TB control, research, laboratory proficiency, 
RTMCCs, workforce issues, and the capacity of the U.S. National TB Program to serve as a 
system. 
DTBE formed three workgroups to focus on contingency budgets for program, research and 
staffing plans, the need for more translational activities, and approaches to incorporate the 
Think Tank’s proposed concepts into the strategic alignment plan.  The workgroups were asked 
to identify DTBE’s priorities based on budget projections of $125 million and $100 million. 
Several events have impacted the timing and direction of DTBE’s strategic alignment process, 
including the 2014 Omnibus budget that deferred the 2013 budget sequestration; comparable 
DTBE funding between the FY2013 and FY2014 levels; and changes to DTBE’s permanent 
leadership in 2014.  Although the FY2014 budget is stable and will not be cut in the immediate 
future, DTBE will maintain momentum on its strategic planning efforts to ensure that TB 
priorities continue to be aligned with its vision, mission and core functions in the future.  The 
stable FY2014 budget also will allow DTBE to consider level funding scenarios.  However, the 
staffing plan most likely will be developed last due to its dependence on and need to be 
informed by the program and research plans. 
These events required DTBE to revise the approach to its strategic alignment process.  
Activities of the program and research plans will be identified, prioritized and aligned with 
strategic priorities that DTBE established in the past.  These activities will be developed 
independently of the $125 million and $100 million budgets that were projected for DTBE.  
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Staffing will be aligned with and optimized for priority activities.  Multiple budget scenarios will 
be applied, including level funding, to the priority program and research agendas.  A list of 
prioritized activities that cannot be funded with existing resources will be compiled and retained 
if additional funds become available or new, more urgent funding requests are made in the 
future. 
DTBE identified its next steps and developed a tentative timeline to complete the strategic 
alignment activities in the second and third quarters of 2014:  complete the program plan, 
research agenda and budget scenarios; initiate the internal CDC vetting process; obtain 
external input from ACET, other key partners and stakeholders; and finalize all of the plans. 
The DTBE Director’s report resulted in ACET making comments and suggestions in the 
following areas.   
• DTBE is to be commended on its intention to obtain broad input on the strategic 
alignment process from ACET and other external sources.  However, DTBE should 
extensively engage front-line TB control programs earlier in the process, particularly in 
the development of the program and research plans. 
• DTBE will establish priorities for its strategic alignment process based on four budget 
scenarios:  FY2014 level funding of $135 million, a $125 million budget, a $100 million 
budget, and priority activities that cannot be supported by current funding.  However, 
DTBE should inform its partners and key stakeholders that the $100 million budget is 
considered to be the “worst-case” scenario. 
• ACET should determine its specific role in helping DTBE to advance the strategic 
alignment process and identify priorities in the current environment of severe budget 
constraints.  For example, ACET could submit a formal resolution to the HHS Secretary 
and the CDC Director to emphasize the following points. 
o “TB is an airborne infectious disease.” 
o “TB is embedded in CDC’s core public health function to control and prevent 
diseases.” 
o “Because significant cuts to the TB budget have tremendously impaired state and 
local programs, DTBE should be held harmless from budget cuts in the future.” 
Update on TB-Related Affordable Care Act Issues 
Ann Cronin 
Associate Director for Policy and Issues Management  
Division of Tuberculosis Elimination 
Centers for Disease Control and Prevention 
Christine Ho, MD, MPH 
Medical Officer, Division of Tuberculosis Elimination 
Centers for Disease Control and Prevention 
Ms. Cronin and Dr. Ho presented an update on the Affordable Care Act (ACA) in the context of 
TB-related issues.  The U.S. Preventive Services Task Force (USPSTF) is funded by the 
Agency for Healthcare Research and Quality (AHRQ) as an independent expert panel to grade 
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screening services based on the quality of treatment and the number of persons needed to treat 
a specific disease or condition in order to prevent a case. 
USPSTF recommendations are extremely important in the current health reform environment 
because ACA does not require a co-pay for screening services with a USPSTF “A” or “B” grade.  
Instead of renewing the existing “A” grade for LTBI screening, USPSTF issued a new 
recommendation that deferred to CDC’s guidelines in order to avoid duplicating efforts and 
resources by another federal agency.  Moreover, coverage of LTBI treatment under ACA is at 
the discretion of each individual state because the federal government has no authority to rule 
or regulate “health.”  ACA requires all states to cover a minimum set of essential health 
services, but each state is allowed to select a benchmark plan of preventive, rehabilitative and 
other services that will be covered. 
The ACA regulations and USPSTF’s decision to defer to CDC’s guidelines instead of renewing 
its existing grade “A” recommendation led to an unintended consequence in which TB screening 
would not be covered without a co-pay.  To resolve this problem, CDC and AHRQ entered into 
an interagency agreement to jointly fund a competitive contract to support USPSTF’s updated 
review of LTBI screening. 
As the awarded contractor, Research Triangle Institute (RTI) will propose a research strategy by 
the end of March 2014 for USPSTF to consider in its updated systematic review.  CDC intends 
to circulate RTI’s proposed research strategy to its internal TB experts, ACET, the National 
Tuberculosis Controllers Association (NTCA) and other key stakeholders for review and 
comment.  RTI’s revised research strategy will be published for broader input before being 
forwarded to the USPSTF systematic review process. 
In the interim of the lengthy process for USPSTF to issue a new grade, states are allowed to 
add TB screening to their state Medicaid plans and TB control programs are free to consult with 
their local health plans to obtain coverage for LTBI treatment.  To support this effort, TB control 
programs should inform their local health plans of the low cost of covering LTBI treatment 
compared to the extremely high cost of covering TB patients who are hospitalized and/or 
isolated. 
ACET advised CDC to re-categorize “LTBI treatment” as “primary” or secondary” prevention of 
active TB disease.  The failure to treat LTBI allows TB cases to continue to transmit disease to 
others.  ACET urged CDC to convey this perspective and provide supporting data to encourage 
USPSTF to renew the grade “A” recommendation for LTBI screening. 
Update by the ACET Essential Components Workgroup 
Eric Brenner, MD 
Adjunct Associate Professor, Department of Epidemiology and Biostatistics 
University of South Carolina 
ACET Member & Essential Components Workgroup Chair 
Dr. Brenner covered the following topics in his update to ACET on the workgroup’s recent 
activities.  The workgroup is represented by ACET members, NTCA, Stop TB USA and other 
key stakeholder organizations.  The workgroup was charged with revisiting and updating 
ACET’s January 1995 recommendations, “Essential Components of a Tuberculosis Prevention 
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and Control Program,” to reflect more recent TB data, the sharp decline in U.S. TB cases over 
the past 20 consecutive years, and the stronger focus on TB elimination rather than TB control 
and prevention. 
The workgroup was unable to meet its proposed timeline of completing the draft updated 
Essential Components report in time for the March 2014 meeting, but the document will be 
presented during the June 2014 meting for ACET’s review, discussion and input.  The 
workgroup is focusing on the following areas to fulfill its charge. 
• The workgroup is aware that NCHHSTP supports the inclusion of TB elimination efforts 
in its HIV/AIDS, viral hepatitis and STD prevention activities.  The workgroup also 
recognizes that NCHHSTP has emphasized the critical need to identify potential 
opportunities to integrate preventive services across all of its infectious disease 
programs.  For example, patients should be able to have their TB, HIV, STD and HCV 
needs met in one prevention visit on the same day. 
• The workgroup reviewed existing guidelines that advised programs to plan for integrated 
service delivery to individual patients, increase the efficiency and effectiveness of 
treatment and preventive measures, aim to improve the health of each patient, and 
diminish the risk of disease transmission.  Based on the workgroup’s literature review, 
~15 sets of recommendations and reports on integrated services have been published 
since 1995.  The workgroup will incorporate key messages from these guidelines into 
the updated Essential Components report. 
• The workgroup’s literature review identified 129 TB-specific articles that have been 
published in the Morbidity and Mortality Weekly Report (MMWR) since 1993.  The 
workgroup will consider key concepts from these publications to include in the updated 
Essential Components report. 
o A 1995 MMWR article emphasized the importance of using alternative approaches 
to TB control (e.g., the expanded use of directly-observed therapy (DOT)).  Since 
that time, however, DOT has become the standard of care by the majority of health 
departments rather than an alternate form of care.  Moreover, the American Thoracic 
Society (ATS)/CDC/Infectious Disease Society of America Treatment Guidelines 
noted that TB control strategies always should include an adherence plan with 
particular emphasis on DOT. 
o The March 31, 2006 MMWR article questioned the health status, treatment 
outcomes and public health impact of 130 patients in New Orleans who were being 
treated for TB during Hurricane Katrina, but were relocated to other cities and might 
still be infectious.  The extensive and collaborative efforts of TB controllers in 
neighboring states led to all 130 TB patients being found to assure completion of TB 
treatment. 
o A 2013 MMWR article described the implications for public health practice to 
address issues related to natural disasters.  The article advised TB control programs 
to continue to conduct systematic planning that would enable a timely response. 
The workgroup’s next steps will be to thoroughly review the MMWR articles to identify specific 
wording to revise for the updated Essential Components report and decide whether the existing 
“Assessment, Assurance and Evaluation” model should be included as a one-page addendum.  
This model is conceptually powerful and widely used by public health, but does not include the 
essential core vocabulary that traditionally has been used to discuss TB programs. 
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Update by the DTBE Corrections Workgroup 
Lauren Lambert, MPH 
Epidemiologist, Division of Tuberculosis Elimination 
Centers for Disease Control and Prevention 
Advice Requested from ACET by DTBE: 
• What are ACET’s next steps to continue its collaboration with the DTBE Corrections 
Workgroup and other correctional partners (e.g., NTCA, Immigration and Customs 
Enforcement (ICE), and Federal Bureau of Prisons (BOP)) to create a national strategic 
action plan to assist in preventing and controlling TB in correctional facilities? 
Ms. Lambert described the Corrections Workgroup’s accomplishments to date in the first part of 
her update to ACET.  DTBE has established strong collaborations with several internal and 
external partners, including various NTCA Corrections Workgroups and the NCHHSTP 
Corrections Coordinator, CAPT Laurie Reid.  DTBE created a corrections slide set with national 
surveillance data that will be revised and updated every two years.  The slide set is available on 
the CDC.gov/tb website under the “TB in Specific Populations” section. 
An online correctional liaison course was created by the Heartland National TB Center with 
input from partners, including DTBE. Extensive interest was shown when the online course was 
piloted in February 2014. NTCA compiled a list identifying at least 1 correctional liaison for each 
state. The list is available on the NTCA website. The DTBE Molecular Epidemiology Activity 
staff is developing genotyping methods to identify corrections-related TB clusters. 
Ms. Lambert focused the second part of her update on ACET’s resolution to the Corrections 
Workgroup that was unanimously approved during the December 2012 meeting.  The formal 
resolution included 20 action items that were addressed. 
ACET RESOLUTION CORRECTIONS WORKGROUP RESPONSE 
Topic 1: Coordination 
Strengthen the coordination and oversight of 
TB prevention and control in correctional and 
detention facilities in partnership with state TB 
programs. 
Fully initiated; DTBE is developing a proactive 
plan that will include a systematic approach to 
address these issues.  The Corrections 
Workgroup has been meeting on a monthly 
basis since January 2013. 
Conduct a formal evaluation to assess the 
need for a full-time equivalent to coordinate 
corrections activities. 
Partially initiated; DTBE created three work 
groups that will focus on the strategic alignment 
of staffing, programs and science for all TB 
activities. DTBE has created 3 strategic work 
groups: Staffing, Programs, and Science. The 
Staffing and Programs work groups will be 
discussing this issue; however, the creation of 
a full-time position to specifically coordinate 
corrections activities will likely not be possible 
in the near future due to the reduction in overall 
staffing within the division.   
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ACET RESOLUTION CORRECTIONS WORKGROUP RESPONSE 
Develop ongoing collaborative partnerships 
with national and regional correctional 
organizations to advance TB education, 
prevention and control efforts. 
Partially initiated; Ms. Tara Wildes, Chief of the 
Jail Division in the Jacksonville (Florida) 
Sheriff’s Office, is now serving as the ACET 
liaison representative for the National 
Commission on Correctional Health.  DTBE 
hopes to collaborate with additional correctional 
liaison representatives in the future from the 
organizations that ACET proposed:  American 
Correctional Association, National Institute of 
Corrections, American Jail Association, 
American Sheriff’s Association, Coalition of 
Correctional Health Authorities, Society of 
Correctional Physicians, and correctional 
health care companies. 
Topic 2: Correctional Liaison Defined in the TB CoAg 
Incorporate language into the 2015 TB CoAg 
for each grantee to designate a correctional 
liaison and include a brief summary of 
activities in their interim and final progress 
reports.  Utilize the “NTCA Public Health TB 
Corrections Liaison Model Duty Statement” as 
a guide in determining local priorities for 
correctional liaisons in each jurisdiction. 
Fully initiated; DTBE has attended meetings 
with CDC staff that is responsible for 
developing and releasing CoAgs.  Language 
similar to ACET’s proposed language will be 
included in the 2015 TB CoAg. 
Topic 3: Surveillance 
Develop a plan for using TB surveillance as a 
programmatic tool to identify the burden of 
disease and the need for interventions.  
Publish a brief annual summary of trends that 
would be widely available and promoted for 
use by state TB programs to guide data-driven 
decisions about resource allocations. 
Fully initiated; DTBE created a corrections slide 
set with national surveillance data that will be 
revised and updated every two years.  The 
slide set is available on the CDC.gov/tb website 
under the “TB in Specific Populations” section. 
Add the following question to the next update 
of the Report of Verified Case of Tuberculosis 
(RVCT):  “History of incarceration in the last 1 
or 2 years.”  
Partially initiated; DTBE will submit a formal 
proposal to add this question when the RVCT 
Workgroup reconvenes in 2015.  In the interim, 
the RVCT Quality Assurance Workgroup is 
revising instructions for this variable. 
Topic 4: TB Case Detection 
Identify methods to improve TB screening, 
case detection and medical management of 
persons with infectious TB. 
Partially initiated; Most impressively with the 
New York City Department of Health and 
Mental Hygiene when the NYC jail system 
piloted a project in 2011 in which the tuberculin 
skin test (TST) was replaced with an interferon 
gamma release assay (IGRA) for routine LTBI 
screening at intake in women’s jail facilities.  
The pilot project was expanded to include all 
men’s jail facilities in August 2012.  New York 
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City is now the largest correctional system in 
the United States that uses IGRA for routine 
LTBI screening at intake.  The pilot project 
showed that of >57,000 men and women who 
were screened for LTBI with an IGRA in New 
York City jails, 4%-5% had positive results. 
Emphasize the appropriate use of rapid testing 
in diagnostic evaluations of persons in the 
legal custody of law enforcement agencies. 
Fully initiated; The October 13, 2013 edition of 
the MMWR published guidelines on the use of 
nucleic acid amplification testing.  Molecular 
Detection Drug Resistance and polymerase 
chain reaction testing were found to be easier 
and faster than obtaining acid-fast bacillus 
(AFB) smear results.  DTBE hopes the 
guidelines will be increasingly used by 
correctional facilities over time. 
Develop algorithms for returning inmates with 
suspected pulmonary TB to the general inmate 
population. 
Fully initiated; CDC and its partners have 
released several sets of guidelines with specific 
criteria and supporting data on releasing 
inmates with TB from airborne infection 
isolation:  Prevention and Control of 
Tuberculosis in Correctional and Detention 
Facilities; Guidelines for Preventing the 
Transmission of Mycobacterium tuberculosis in 
Healthcare Settings; and Controlling 
Tuberculosis in the United States.  The 
guidelines recommend that institutions collect 
three negative AFB smears before hospitalized 
TB patients are returned to a congregate 
setting, homeless shelter or detention facility.  
However, ICE is developing new algorithms 
that will provide more detailed and specific 
action steps than the criteria outlined in the 
current guidelines to return inmates and 
detainees with TB to the general population. 
Topic 5: Continuity of Care 
Conduct state-specific analyses to determine 
the rationale for the low rate of TB treatment 
completion among persons incarcerated at 
diagnosis.  Collaborate with state and local 
health departments to improve TB treatment 
completion rates. 
Partially initiated; DTBE agrees that these 
analyses are important and could play an 
instrumental role in compiling best practices 
and developing other tools based on the 
performance of states with high TB treatment 
completion rates.  Several states are partnering 
with DTBE at this time to conduct analyses as 
an initial effort to improve their TB completion 
rates.  The 2012 Mitruka study showed that 
incarcerated persons had a four-fold higher risk 
for TB, but were less likely than non-
incarcerated persons to complete TB 
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treatment.  The Mitruka follow-up study, 
“Trends and Predictors of No Treatment 
Completion Among Incarcerated Persons at 
Diagnosis (1999-2009)” is being conducted at 
this time. 
Evaluate the effectiveness of CURE-TB and 
TB-NET for transnational TB referrals and 
explore long-term funding. 
Partially initiated. DTBE works with these 
organizations and the DTBE Corrections 
Workgroup plans to reach out to these 
partners.  
Explore the possibility of establishing a central 
system to obtain TB treatment completion data 
on patients who have been repatriated back to 
their countries of origin. 
Deferred; No formal or systematic notification 
process has been created between CDC in the 
United States and foreign countries.  The 
International Research and Programs Branch 
of DTBE notifies the country of origin and 
attempts to obtain TB treatment completion 
data when foreign-born TB patients return to 
the United States.  However, this action can be 
taken only if states are made aware of and 
inform DTBE of the return of foreign-born TB 
patients to the United States or back to their 
country of origin. 
Identify programs that have a successful track 
record of improving continuity of care and 
increasing treatment completion rates of TB 
cases in correctional facilities.  Disseminate 
information about these effective models. 
Partially initiated; DTBE is requesting that 
states will report successes to us in order to 
produce a best practices documents. 
Topic 6: TB Education 
Instruct the RTMCCs and appropriate DTBE 
branches to coordinate strategies to identify 
and meet TB learning needs of correctional 
administrators, correctional HCPs and 
infection control personnel, law enforcement/ 
correctional officers, and inmates.  Conduct 
the following activities to support this effort: 
• Conduct a needs assessment. 
Partially initiated; The Southeastern National 
TB Center conducted a needs assessment of 
correctional liaisons in each state and currently 
is analyzing the data.  NTCA will produce a 
report of these findings. 
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• Develop, disseminate and evaluate TB 
educational tools. 
Partially initiated; The Heartland National TB 
Center piloted an online correctional liaison 
course in February 2014.  DTBE is pleased that 
two courses, “Arresting TB: Best Practices for 
Controlling TB in Corrections” and “Contact 
Investigation and Discharge Release Planning,” 
were extremely well received.  NCHHSTP 
developed a new document with an overview of 
model integrated programs and a description of 
integrated health services, including TB, that 
potentially could be offered in prisons.  The 
document currently is undergoing the CDC 
clearance process. 
• Develop TB competency assessment 
tools for correctional HCPs. 
Partially initiated; NTCA has created 
competencies for nurse consultants and TB 
case managers.  The competencies are now 
available on the “Resources” section of the 
NTCA website, but efforts are underway to 
more prominently feature this tool on the NTCA 
home page. 
• Collaborate with correctional partners to 
identify methods to assure correctional 
HCPs and infection control staff receive 
TB education and strategies are available 
to demonstrate TB competency. 
Fully initiated; The RTMCCs have developed 
an on-line “Correctional Liaison Training 
Course.”  DTBE currently is developing a slide 
set for non-medical correctional workers. 
Topic 7: Treatment of LTBI 
Fully initiated; CDC published guidelines in 
October 2013 on the use of the 12 dose 
regimen of isoniazid and rifapentine for LTBI 
treatment. The 3HP regimen has been piloted 
at the national level by BOP and at the local 
level by a county jail in Santa Clara, California.  
Both of these pilot projects currently are in the 
post-marketing phase. However, DTBE looks 
forward to receive results from other 
correctional settings that have implemented the 
3HP regimen. 
Identify approaches to expand treatment of 
LTBI in correctional facilities, including 
expanded use of the three-month, once-
weekly isoniazid/rifapentine (3HP) regimen. 
Topic 8: Funding 
Partner with key stakeholders to leverage 
existing and future resources for TB 
prevention and control in correctional and 
detention facilities (e.g., funding and resources 
for PCSI activities; emergency preparedness 
programs; HIV, viral hepatitis and diabetes-
related organizations; programs that serve 
immigrant populations; and national 
correctional organizations). 
Ongoing; DTBE is challenged in taking action 
on this recommendation at this time in the 
current era of severe budget constraints.  
However, funding issues will be maintained as 
a critical agenda item during the monthly 
meetings of the Corrections Workgroup. 
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Ms. Lambert concluded her update by describing the progress the Corrections Workgroup along 
with multiple partners, has made to date in accomplishing the 20 action items in ACET’s 
resolution.  She explained that two categories were added, “Deferred” and “Ongoing.”  Most of 
the steps that have been “fully” or “partially initiated” are also “Ongoing.” 
• The number of action items that the Corrections Workgroup has “fully initiated” increased 
from 1 in 2013 to 8 in 2014. 
• The number of action items that the Corrections Workgroup has “partially initiated” 
decreased from 15 in 2013 to 10 in 2014. 
• The number of action items that the Corrections Workgroup has “not initiated” decreased 
from 4 in 2013 to 0 in 2014. 
ACET commended DTBE and its Corrections Workgroup partners on their outstanding efforts, 
accomplishments and rapid progress.  ACET made several comments and suggestions for the 
workgroup to consider in its ongoing activities. 
• The new TB corrections algorithms and updated TB corrections guidelines should 
provide instructions for facilities to coordinate efforts, clearly define their jurisdictional 
authority and responsibilities, and assure equitable TB care regardless of the inmate 
“type.”  Guidance on TB prevention, control and care vary among federal, state and local 
correctional facilities.  For example, a local jail immediately would screen short-term 
inmates for TB at intake, but the same local jail would only hold federal detainees for 
pick-up with no TB screening.  The new algorithms and guidelines should emphasize the 
importance of correctional facilities applying the same TB prevention, control and care 
measures regardless of whether the individual is a short-term inmate in a jail, a long-
term state prisoner or a federal detainee. 
• The Corrections Workgroup should explore the possibility of conducting an additional 
activity under the “surveillance” category.  Arizona, California, Florida, Georgia and 
Texas account for 70% of all TB cases in U.S. correctional facilities.  The workgroup 
should collect and thoroughly review TB surveillance data from correctional facilities in 
these five states to determine smear positivity rates as a proxy for diagnostic delay and 
treatment completion rates with cavitary X-ray as a proxy for diagnostic delay.  These 
data analyses would be extremely helpful in characterizing the source of problems 
related to delays in diagnosing TB in correctional facilities. 
• The Corrections Workgroup should administer a survey to determine vitamin D intake 
among incarcerated populations. 
• The Corrections Workgroup’s proposal to add a question to the next update of the RVCT 
should be worded as follows:  “Has the patient ever been incarcerated?  If yes, when 
was the patient’s most recent incarceration?”  The question should be worded in this 
manner because the time between TB infection and disease greatly varies.  A focus on 
the patient’s history of incarceration for the past one or two years only might overlook 
persons who acquired TB infection in prison. 
Update on TB Drug and Biologic Shortages in the United States 
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Donna Wegener 
Executive Director 
National Tuberculosis Controllers Association 
Advice Requested from ACET by NTCA: 
• What guidance can ACET provide to HHS on actions that should be expedited to ensure 
further consequences of TB drug and biologic shortages for TB programs and patients are 
avoided? 
Ms. Wegener described ongoing national efforts by NTCA and its partners to address TB drug/ 
biologic shortages.  The TB drug supply is vulnerable and includes numerous weaknesses:  few 
drug options for multi-drug regimens, a limited number of manufacturers, current shortages that 
are continuing to worsen, increases in drug costs, and the absence of a safety net for a drug 
supply.  Of the 4 first-line drugs (FLDs), 3 have a shortage or have experienced a large price 
increase.  Of the 8 second-line drugs (SLDs), 5 are produced by a single manufacturer. 
NTCA partnered with the Treatment Action Group (TAG) and the Program for Appropriate 
Technology in Health to co-host a high-level meeting on January 15, 2014.  The purpose of the 
meeting, “Solving the Silent Crisis,” was to resolve and prevent domestic TB drug shortages and 
serve as a follow-up to the larger conference that TAG convened in January 2013 to address 
the isoniazid (INH) shortage.  The 2014 meeting served as a platform for a diverse group of 
federal and national organizational partners to explore interagency solutions to more effectively 
prevent and respond to TB drug/biologic shortages. 
The opening presentation described the background and need for the “Solving the Silent Crisis” 
meeting.  Progress in TB control and elimination in the United States increasingly is threatened 
by problems in accessing life-saving TB drugs/diagnostics.  Interruptions in the domestic TB 
drug supply have worsened.  The fragmented nature of the domestic TB procurement system 
has created instability in markets and supplies.  Communications and reporting systems among 
federal agencies and between federal agencies and state/local TB programs are inadequate.  
Few manufacturers for TB products exist at this time. 
Other presentations focused on current TB procurement strategies available to U.S. programs, 
models implemented in other countries (e.g., Brazil, Canada and the United Kingdom) that 
potentially could be adapted in the United States, and the Global Drug Facility (GDF).  The 
partners agreed on the merit and value of exploring GDF as a promising and economical option 
to address TB drug/biologic shortages in the United States. 
The “Solving the Silent Crisis” meeting report recommended immediate, ongoing and future 
action items.  For the immediate action item, a rotating inventory reserve system will be 
developed to address acute TB drug shortages and create a strong TB drug safety net.  For the 
ongoing action items, emphasis will be placed on creating a centralized procurement system in 
the United States, expanding the pool of U.S. suppliers, increasing the number of markets to 
maintain existing U.S. suppliers, and improving interagency communications. 
For the future action items, two key areas will be targeted to achieve the goal of obtaining a 
more stable and affordable TB drug supply in the United States.  First, a rotating, vendor-
managed inventory reserve will be created.  The quantity of the current TB drug supply will be 
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determined.  A tracking system will be developed to forecast and monitor the national supply of 
TB drugs/biologics.  New and necessary resources will be determined. 
Second, the pool of U.S. suppliers will be expanded.  FDA will explore the possibility of 
expediting reviews of products that already have been approved under stringent regulatory 
authorities as well as waiving or reducing registration fees for life-saving TB drugs.  GDF will 
help to provide incentives for manufacturers to register in the United States.  NTCA will provide 
FDA with a list of medically necessary TB drugs.  ATS will draft language to enhance FDA’s 
capacity to collaborate with CDC and GDF to resolve TB drug shortages. 
The partners have made tremendous and rapid progress in currently conducting or completing a 
number of the recommended action items:  compiling a list of medically necessary TB drugs; 
investigating the possibility of developing an inventory reserve system; creating a schematic and 
a process to monitor risks to the TB drug supply in the United States; and including language in 
the reauthorization of the Comprehensive TB Elimination Action to support FDA’s regulatory 
actions. 
The next steps by the partners to develop a centralized procurement system will be to explore 
funding options and design a U.S. model based on the GDF model.  FDA will evaluate recent 
TB drug shortages and breakdowns in communications to facilitate the creation of a cross-
cutting system.  Beginning in the spring of 2014, NTCA and TAG will jointly convene additional 
meetings with an expanded group of stakeholders, including industry representatives, to discuss 
progress from the “Solving the Silent Crisis” meeting and identify unresolved gaps. 
Prior to co-hosting the “Solving the Silent Crisis” meeting in January 2014, NTCA explored the 
possibility of creating the first system in the United States to formally collect, maintain and report 
data on TB drug/biologic shortages.  Multiple state and local health departments and community 
partners across the country reported Tubersol shortages to NTCA.  NTCA also recognized that 
drugs are the strongest tools in the TB arsenal.  Drugs that are not available or are too 
expensive for TB programs and patients to purchase undermine public health efforts to control, 
prevent and ultimately eliminate TB.  
NTCA’s initial effort in the development of a reporting system for TB drug/biologic shortages 
was to solicit input from and initiate a vetting process with multiple states, partners and TB 
programs in the field.  NTCA used this feedback to identify the most appropriate data elements 
to collect and determine the most efficient format to gather information.  NTCA also was aware 
that participation by state and local TB programs and community partners would be greater with 
an easy and streamlined reporting system requiring minimal time and burden. 
NTCA launched its new web-based system in November 2013 to collect, maintain and report 
the following data elements on TB drug/biologic shortages. 
• TB drug/biologic shortage data, including specific dates, manufacturers, suppliers and 
affected unit dosages 
• Impacts of shortages or price increases on TB programs and patient care 
• Price data, including dates and actual costs supported by invoices 
• Organizational data, including the organization’s location, type and participation in drug 
procurement programs 
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NTCA acknowledges the limitations of preliminary data on its web-based reporting system for 
TB drug/biologic shortages.  The three-month data collection period from November 21, 2013 to 
March 2, 2014 was extremely short.  Data were gathered after the Tubersol shortage and after 
production had resumed due to the resolution of manufacturing issues.  State TB programs 
were experiencing tremendous problems in accessing TB drugs/biologics.  Active follow-up and 
efforts to market NTCA’s new web-based reporting system have been minimal to date. 
Preliminary results of NTCA’s new web-based reporting system are highlighted as follows.  
Several states and counties, Puerto Rico and the Northern Mariana Islands have submitted 62 
reports to NTCA to date.  County TB programs (~48%) and state TB programs (~35%) 
accounted for the top two organizational types that submitted reports to NTCA.  Correctional 
facilities and regional TB programs that cover >2 counties or cities each accounted for 4.4% of 
reports.  Hospitals, pharmacies, city TB programs and federal agencies each accounted for 
2.2% of reports.  A county government employee health center, a home healthcare facility and a 
public health laboratory accounted for the remaining three reports. 
Various TB drugs/diagnostics have been reported to the NTCA system to date:  Tubersol (60%), 
Pyrazinamide (PZA) (19%), Aplisol (9%), INH (3%), Ethambutol (EMB) (3%), Kanamycin (KAN) 
(2%), Cycloserine (2%), and Rifamate (2%).  Manufacturers with reported TB drug/diagnostic 
issues were Sanofi Pasteur (~62%), VersaPharm (~18%), JHP Pharmaceuticals (~11%), Chao 
Center (~2%), and Sandoz (~2%).  The types of issues reported included shortages (66%), 
price increases (23%), a combination of shortages/price increases (9%), and other issues (e.g., 
a recall on EMB) (2%). 
TB drugs/diagnostics with reported shortages included Tubersol (76%), Aplisol (13%), INH 
(3%), KAN (3%), Cycloserine (3%), and EMB (2%).  TB drugs/diagnostics with reported price 
increases included PZA (84%), INH (8%), and Rifamate (8%).  Of the respondents that reported 
a Tubersol shortage, 78% described changes in their routine practice of testing for TB infection.  
The most common changes reported by respondents were prioritized TB testing to high-priority 
groups (83%), delayed TB testing (63%), and no testing of low-priority groups (48%). 
The Tubersol shortage resulted in TB programs delaying or temporarily suspending testing to 
persons seeking TB screening for work or school (64% of programs), HCPs (40% of programs), 
substance abuse treatment center residents and outpatients (28% of programs), shelter clients 
(24% of programs), and TST or IGRA converters with a documented TB test in the past two 
years (20% of programs).  Programmatic decisions to delay or temporarily suspend TB 
screening of some groups (e.g., emergency medical services personnel, firefighters and other 
first responders) due to the Tubersol shortage are of particular concern and might place the 
safety of some communities at risk. 
The current price of PZA of $153 for 100 tablets has doubled or tripled in Alabama, Oregon, 
Puerto Rico and Vermont in a one-year time period.  The per-tablet cost of PZA has increased 
from ~$0.70 to ~$1.50 in some states.  The price increase of PZA has required several states to 
purchase more expensive substitutes or switch to a sub-optimal treatment regimen.  NTCA has 
initiated dialogue with the manufacturer of PZA to better understand the rationale for the rapid 
price increase.  NTCA will continue to report key outcomes of these discussions to CDC and 
FDA. 
Overall, NTCA’s new web-based system will serve as an important tool for real-time data 
reporting.  Preliminary data from the system showed that shortages in the TB drug/diagnostic 
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supply are continuing to interrupt and negatively impact patients and programs.  Multiple states 
increasingly are experiencing difficulties in accessing Tubersol on an ongoing basis.  Due to the 
significant price increase of PZA, some states have omitted this essential drug from their TB 
regimens. 
NTCA will continue to collaborate with its partners to address risks in several areas.  A single 
manufacturer produces a large percentage of FLDs and SLDs.  Interruptions in the TB drug/ 
diagnostic supply, cost increases and barriers to access have increased and made the 
procurement system more vulnerable.  Both short- and long-term strategies need to be 
expedited. 
Ann Cronin 
Associate Director for Policy and Issues Management  
Division of Tuberculosis Elimination 
Centers for Disease Control and Prevention 
Advice Requested from ACET by DTBE: 
• What guidance can ACET provide to assist DTBE in developing a long-term plan for an 
uninterrupted supply of all TB drugs and diagnostics? 
Ms. Cronin described ongoing national efforts by DTBE to address TB drug/biologic shortages.  
DTBE recently compiled a list of drugs/biologics that all TB and LTBI patients in the United 
States would need for a six-month supply.  DTBE forwarded the list to the USPHS Supply 
Service Center, the drug distribution center for the entire U.S. government (USG), with a 
request to obtain the cost of purchasing all of the TB drugs/biologics at the same time through a 
centralized procurement system.  DTBE was extremely surprised that the estimated cost of 
purchasing a six-month supply of drugs/biologics for all TB and LTBI patients in the United 
States would be $21 million.  TST and SLDs accounted for the majority of the purchase price. 
DTBE has assumed for a long period of time that the importation of drugs through GDF would 
be virtually impossible due to FDA’s inability to assure the quality of drugs entering the United 
States.  However, DTBE consulted with GDF to review the current TB drug schedule and 
determine the types of approvals that are available at this time.  DTBE was pleased to learn that 
three drugs sold through GDF are available in a U.S. FDA-approved formula:  Cycloserine, KAP 
and Para-Aminosalicylic Acid (PAS).  DTBE has informed TB programs that are unable to 
procure these three SLDs through regular mechanisms of their ability to purchase the drugs 
directly from GDF.  TB programs also were directed to the GDF website to obtain forms and 
instructions on ordering and purchasing drugs. 
DTBE also learned that some overseas drug manufacturers are U.S. subsidiaries.  During a 
recent teleconference, FDA and USAID informed DTBE that TB programs could purchase U.S. 
FDA-approved subsidized drugs through GDF.  DTBE will continue its dialogue with FDA and 
USAID to explore strategies to expand the number of FDA-approved drugs that are available 
through GDF and provide TB programs with a wider selection of products.  Instead of taking 
action on the “Solving the Silent Crisis” recommendation to design a centralized procurement 
system in the United States based on the GDF model, U.S. TB programs might be able to 
directly access the GDF model. 
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ACET discussed the following topics during the question/answer session with Ms. Wegener and 
Ms. Cronin on ongoing efforts to address TB drug/biologic shortages in the United States. 
• The rationale for some programs retesting TST or IGRA converters who have a 
documented TB test within the past two years. 
• Marketing strategies to widely publicize the availability of NTCA’s web-based system to 
increase reporting of TB drug/biologic shortages, particularly among correctional 
facilities. 
• The need to encourage FDA to take concrete action steps (e.g. reducing fees, granting 
waivers or expediting the approval process) to remove regulatory barriers for companies 
that supply TB drugs to GDF. 
ACET advised CDC to consult with two groups that currently are focusing on antimicrobial 
resistance:  the Restricted Interagency Policy Committee on National Preparedness for 
Combating Antibiotic-Resistant Bacteria and the President’s Council of Advisors on Science and 
Technology.  The purpose of CDC’s collaboration with these two groups would be to explore 
strategies to stimulate the development of anti-pyogenic drugs and secure a better TB drug 
market in the United States.  ACET emphasized that the prices of TB drugs in the GDF stockpile 
will steadily rise as the number of cases continues to decline. 
Update on CDC’s Global TB Activities 
Susan Maloney, MD, MHSc 
Global TB Coordinator, Center for Global Health 
Centers for Disease Control and Prevention 
Advice Requested from ACET by CDC: 
• What are ACET’s recommendations to CDC in the following areas? 
o CDC’s global TB measures and targets 
o The membership and structure of the proposed Global TB Steering Committee 
o CDC’s proposed Global TB Strategic Framework and critical elements for the Global 
TB Strategic Plan 
o Effective approaches to expand and sustain the “TB Building and Strengthening 
Infection Control Strategies” (BASICS) Initiative 
Dr. Maloney presented an update on CDC’s global TB coordination activities.  Global TB 
activities at CDC are conducted by three National Centers and four divisions.  Despite 
differences in their mandates, organizational structures and funding streams, all of these entities 
have a long history of collaboration and coordination on global TB issues. 
An expert panel conducted a peer review of CDC’s global TB portfolio in November 2012 and 
made recommendations in two major areas.  First, CDC should develop a forward-looking, 
agency-wide Global TB Strategy that prioritizes 2-3 focus areas:  (1) application of CDC’s core 
competencies to a wide range of TB issues (e.g., epidemiology, disease surveillance, research, 
laboratory training, infrastructure development, infection control, and translation of evidence-
based polices into action); (2) factors driving the TB epidemic (e.g., HIV/AIDS, MDR-TB and 
diabetes); and (3) TB in vulnerable populations. 
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Second, CDC should implement a mechanism to increase internal and external coordination, 
communication and advocacy; build broader partnerships; and optimize utilization of its 
resources for a greater impact on global TB. 
In response to the peer review panel’s recommendation to increase internal and external 
coordination, CDC established a new Global TB Coordination Office (GTBCO) with several 
goals.  Leadership and coordination will be provided for the development and implementation of 
CDC’s unified global TB goals, strategies and programmatic priorities.  Internal and external 
communication, coordination and collaboration will be improved through stakeholder meetings, 
workgroups, consultations and implementation planning.  GTBCO will seek to increase 
programmatic synergies and as much as possible optimized utilization of resources to maximize 
impact. 
CDC’s role in implementing the USG Global TB Strategy will be strengthened.  Substantial 
support and contributions will be targeted to achieving the 2011-2015 goals of the Global Plan 
to Stop TB.  Strategic information will be shared more effectively with external partners to help 
identify adequate resources to achieve the goals.  Leadership and coordination will be provided 
for initiatives identified by the CDC, Center for Global Health and NCHHSTP Directors. 
GTBCO is conducting a number of activities to meet its global TB coordination goals.  GTBCO 
is being established as an agency-wide focal point for CDC’s global TB activities by leading 
internal and external data calls with key partners, responding to media and information 
requests, convening briefings, and hosting international visitors and Congressional delegations.  
GTBCO has developed solid relationships with several partner organizations to improve TB 
control efforts in Asia, Africa and other countries, including the World Health Organization 
(WHO), Stop TB Partnership, Global Fund, International Union Against TB and Lung Disease 
(IUATLD), and Ministries of Health (MOHs). 
GTBCO and its federal partners provided technical assistance (TA), subject-matter expertise 
and input to the Center for Strategic International Studies (CSIS).  CSIS was funded by the 
Gates Foundation to perform a one-year analysis of global TB activities and develop a policy 
paper with recommendations to the Obama Administration.  A white paper from the CSIS 
analysis, Tackling TB Abroad: The Answer to TB Elimination in the United States, will be of 
particular interest to ACET for its focus on domestic TB.  GTBCO began holding stakeholder 
meetings to improve coordination and communication.  GTBCO’s new TB BASICS Initiative led 
to the establishment of the new TB Infection Control Workgroup. 
GTBCO serves as a co-chair on the Global TB Workgroup and helped to develop CDC’s 2012-
2015 Global Health Strategy to achieve the goal of a unified Global TB Strategy.  The 
workgroup defined the global TB objective as “reducing TB morbidity and mortality” and also 
reviewed several existing indicators to create unified global TB measures and targets in CDC-
supported countries that would be used to monitor impact in these areas over time: 
• The percent of TB patients with known HIV status 
• The percent of HIV/TB patients on antiretroviral therapy 
• The number of countries reaching the global targets to reduce TB mortality 
• The number of countries reaching the global targets to reduce TB prevalence 
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• The percent of MDR-TB cases detected based on WHO’s estimates of the MDR-TB
burden
The workgroup’s recent global TB strategic planning efforts resulted in several significant 
outcomes, including the creation of an information packet with details on CDC’s unified Global 
TB Strategy; publication of the CDC Annual Global Health Report describing accomplishments 
and progress toward meeting the global TB measures and targets; and agreement to establish a 
Global TB Steering Committee that would be more formal than the existing workgroup. 
The proposed charge of the Steering Committee will be provide oversight and guidance on 
developing and implementing CDC’s unified Global TB Strategy; increase programmatic 
coordination and synergies; and make recommendations on resources that will be needed to 
achieve CDC’s global TB goals.  Specific activities that have been proposed for the Steering 
Committee include providing feedback on the draft Global TB Strategy, offering TA to 
strengthen regional and local coordination and collaboration, and providing oversight of the TB 
BASICS Initiative.  Multiple divisions and offices across CDC Headquarters and in the field have 
been proposed as Steering Committee members. 
GTBCO, in collaboration with CDC global TB stakeholders, drafted a framework outlining the 
strategic approaches, priority areas and specific divisions involved in developing and 
implementing CDC’s Global TB Strategy. 
Strategic Approach Priority Area Responsible Divisions 
Strengthen in-country capacity 
and provide technical support 
Surveillance and impact 
measurement 
Laboratory systems 
Division of Tuberculosis Elimination 
Division of Global HIV/AIDS 
Build an evidence base for 




Division of Global Health Protection 
Translate research into 
practice to inform decision-
making 
TB infection control 
Vulnerable populations 
Division of Global Migration and 
Quarantine (DGMQ) 
Division of Health Care Quality 
Promotion 
The workgroup will update CDC’s Global TB Strategy to emphasize critical elements:  (1) 
ensure a strong programmatic and geographic focus; (2) optimize onsite TA and planning 
overseas with long-term TA models, one-country CDC and USG Global TB plans, and capacity 
building through fellowships; (3) strengthen and expand partnerships; and (4) improve metrics 
for monitoring and measuring impact.  The revised Global TB Strategy will be shared with the 
new Steering Committee and external stakeholders over the next four months for review and 
comment.  After the Global TB Strategy is finalized, an implementation plan will be developed. 
In addition to its global TB strategic planning efforts, GTBCO also has been focusing on the 
important, but often neglected issue of TB infection control.  Low- and middle-income countries 
account for 90% of the global TB burden due to their high rates of disease and limited 
resources.  Because the majority of these resources are targeted to case detection and short-
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course DOT, infection control strategies typically are not implemented, awareness of risks to 
HCPs and patients often is lacking, and HCPs frequently are assumed to be already infected. 
Studies have shown that implementation of TB infection control interventions, including 
relatively inexpensive measures, are associated with a decline in TB outbreaks.  However, 
evaluations to determine the impact of TB infection control are challenging due to the primary 
focus on process rather than impact indicators, the difficulty in demonstrating and measuring 
reduced transmission, and the use of TB and LTBI in HCPs as surrogates. 
Data on nosocomial transmission are limited, but the 2006 Joshi, et al. study indicated a large 
burden.  The study estimated ranges of LTBI and TB disease among HCPs in low- and middle-
income countries:  LTBI prevalence of 33%-79% with an average of 54%; annual risk of LTBI of 
0.5%-14.3%; annual incidence of TB disease of 69-5,780/100,000 population; and attributable 
risk for TB disease of 25-5,361/100,000 population.  LTBI and TB disease in these settings were 
found to be consistently higher than in the general population and also linked to the degree of 
TB exposure and the absence of TB infection control measures.  Data on the implementation of 
TB infection control also are limited, but indicators suggest these measures are inadequate or 
absent in many settings. 
CDC acknowledges that opportunities to improve TB infection control globally are imperative 
and critically important because of the dual epidemics of HIV and drug-resistant TB.  Available 
TB infection control strategies that are relatively simple and inexpensive have been proven to 
decrease transmission, generate a long-term impact on the workforce and healthcare system, 
prevent other diseases and protect patients. 
To make progress in this area, Dr. Thomas Frieden, Director of CDC, issued a directive in April 
2013 for CDC programs to prioritize and accelerate efforts to strengthen TB infection control.  
He emphasized the need for a new initiative with an integrated response to rapidly identify and 
interrupt nosocomial TB transmission.  The new initiative should result in the public health 
outcomes of a greater number of TB cases averted and more lives saved through increased TB 
case detection and decreased TB transmission. 
Dr. Frieden also encouraged collaboration between CDC programs and external partners to 
maximize impact through TB infection control assessments, interventions, evaluations and 
scale-up of activities.  In response to Dr. Frieden’s directive, multiple CDC divisions jointly 
designed TB BASICS to assist countries with high TB, MDR-TB and/or HIV burdens in 
assessing and improving TB infection control in healthcare facilities. 
CDC established several key objectives for TB BASICS:  develop rapid and robust TB infection 
control assessment tools for adoption in the local context; design tailored TB infection control 
intervention packages to address gaps; develop effective monitoring and evaluation plans, 
including indicators and benchmarks; and answer key programmatic and operations research 
questions. 
Training and capacity building in the four areas of TB BASICS (rapid assessment, intervention 
planning, implementation of interventions, and monitoring and evaluation) will be targeted to 
multiple audiences:  MOH stakeholders, healthcare facility staff, implementation partners, 
country-based CDC/field staff, and CDC Headquarters staff. 
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CDC has conducted several activities and made numerous accomplishments in TB BASICS to 
date.  The best and most promising TB infection control tools were identified, collected and 
compiled in an inventory.  TB infection control assessment and intervention tools were adapted 
for inpatient and outpatient settings. 
The TB BASICS Toolkit was designed with the following TB infection control resources:  
national, local and facility background information forms; standard operating procedures and a 
protocol; templates for a facility checklist, report and recommendations; an indicators dashboard 
and other planning and intervention tools; and slide sets, videos and other training resources.  
Mumbai, India was selected as the site to pilot the initial toolkit and validate the process in 
November 2013.  The second pilot will be conducted in Zimbabwe, Africa to test the toolkit in a 
setting with a higher HIV burden, and the first collaborative planning visit is set for March 2014. 
CDC’s next steps will be to apply lessons learned and experiences from the two TB BASCIS 
pilot sites to additional sites.  Approaches will be identified for countries to take leadership of 
and sustain their individual TB BASICS plans over time.  For example, CDC will support a TB 
BASICS Fellow to develop a Nigeria-specific plan to launch and implement the model from a 
country level.  CDC, WHO, USAID and other global partners will co-sponsor a consultation in 
May 2014 to build consensus on the development of TB infection control indicators and 
monitoring and evaluation plans. 
The TB BASICS Toolkit will be enhanced with additional resources, including quick-learn videos 
and iPad/iPhone applications.  Additional resources will be identified to increase support and 
sustainability of TB BASICS.  Collaborative efforts will be undertaken with Kenya and Mumbai to 
fill important gaps in global TB operational research:  an evaluation of the relative impact and 
cost effectiveness of TB infection control interventions; HCP surveillance models; the use of 
molecular epidemiology to better understand the transmission dynamics of TB in healthcare 
facilities; and best practices for environmental assessments and interventions in resource-
limited settings. 
Overall, CDC plans to maximize its impact on global TB by following a roadmap with specific 
components:  publication of the Global Health Strategy and Global TB Strategy; optimized 
coordination, communication and collaboration; engagement of broader partnerships; and 
dedicated funding to empower strategic investments based on core competencies. 
ACET discussed the following topics during the question/answer session with Dr. Maloney on 
CDC’s global TB activities. 
• Opportunities for integration and coordination between the CDC and USAID global TB 
portfolios, such as plans by both agencies to develop models of long-term TA overseas. 
• CDC’s collaboration and consultation with WHO and other global partners to assure the 
following:  (1) CDC’s in-country presence is welcome, respectful, and culturally sensitive/ 
appropriate; (2) CDC’s “stronger and more sophisticated infrastructure of American 
power, funding and expertise” will not overpower or entirely dilute the country’s ongoing 
global TB activities. 
ACET made comments and suggestions in two areas for CDC to strengthen the role of its 
domestic TB portfolio in global TB activities.  First, the operational research questions that CDC 
plans to address with Kenya and Mumbai to build global TB infection control capacity also 
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should be directed to U.S. TB programs.  Emphasis on these same issues at national, state and 
local levels could play an important role in improving TB infection control in the United States. 
Second, CDC should increase collaborative opportunities for DGMQ and DTBE to inform the 
other division of their global and domestic TB control efforts on an ongoing basis.  The DGMQ/ 
DTBE collaboration particularly should focus on continuity of care, drug resistance status and 
treatment outcomes of foreign-born TB patients who are evaluated overseas upon their U.S. 
arrival and foreign-born TB patients in the United States who return to their countries of origin.  
ACET reiterated the need for DTBE’s domestic TB control programs to play a greater role in 
CDC’s global TB infection control and elimination efforts. 
Public Comment Session 
Ms. Cole opened the floor for public comments; none of the participants responded. 
ACET Business Session 
Ms. Cole opened the business session and called for ACET’s review, discussion and/or formal 
action on the following topics. 
Topic 1: Adoption of the Draft ACET Meeting Minutes 
Ms. Cole entertained a motion for ACET to approve the previous meeting minutes.  A motion 
was properly placed on the floor and seconded by Drs. Eric Brenner and Robert Horsburgh, 
respectively, for ACET to approve the previous meeting minutes. 
ACET unanimously adopted the Draft December 3, 2013 Meeting Minutes with no 
changes or further discussion. 
Topic 2: IGRA Resolution 
The presentation of the IGRA resolution was TABLED due to the need to refine the language.  
Dr. Susan Dorman, an ACET member, confirmed that she would present the revised resolution 
during the June 2014 meeting for ACET’s review, discussion and formal vote. 
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Topic 3: Action Items 
Ms. Cole led ACET in a review of the action items and other tasks that were raised over the 
course of the meeting. 
• CDC will provide ACET with clarification on specific criteria that were used to categorize 
and define “antibiotic-resistant infections.”  ACET expressed concern that CDC’s 2013 
report, Antibiotic Resistance Threats in the United States, classified gonorrhea as an 
“urgent” threat and MDR-TB as a “serious” threat. 
• ACET will routinely revisit DTBE’s strategic priorities and proposed budget scenarios to 
monitor their impact on state and local TB control programs over time. 
• ACET will develop formal guidance to assist CDC in its ongoing efforts to obtain a 
USPSTF grade for TB preventive care and Medicaid coverage of this service.  Although 
USPSTF’s sole focus is on targeted TB screening, ACET’s position is that treatment of 
active TB disease and LTBI also should be included as preventive services and eligible 
for Medicaid coverage.  To prepare for ACET’s development of a formal resolution on 
this issue, the members were asked to consult with and obtain input from their local and 
state agencies that are responsible for managing ACA plans. 
• ACET will provide the Essential Components Workgroup with more specific guidance on 
its proposed framework.  To guide this effort, the workgroup will present a draft 
document during the June 2014 meeting for ACET’s review, discussion and ongoing 
input. 
• ACET will propose strategies to widely publicize that written guidelines on TB prevention 
and control are available for incarcerated populations. 
• ACET will continue to provide CDC, NTCA and their partners with concrete advice on 
their ongoing efforts to address TB drug/biologic shortages in the United States.  Most 
notably, ACET agreed to review the key issues for action outlined on the form for this 
agenda item to determine whether a formal resolution should be drafted for any of these 
issues.  Ms. Wegener agreed to post a new link on the NTCA website to the GDF 
website to inform state, large-city and county TB programs of their ability to purchase 
Cycloserine, KAP and PAS directly from GDF. 
• ACET will review TB BASICS in more detail to identify opportunities in which CDC could 
apply global experiences, lessons learned and research from this initiative at national, 
state and local levels in the United States. 
• ACET noted that CDC has not formally responded to many of its consensus resolutions.  
For example, ACET has not received feedback on its recent letter to the HHS Secretary.  
ACET is unaware of the status of its resolution for the HHS Secretary to establish a 
national TB drug stockpile.  Several ACET members viewed the shortage of TB drugs/ 
biologics in the United States as a priority issue and drafted a resolution in this regard 
during the current meeting.  However, the members were unwilling to present the 
resolution because CDC had not formally responded to or taken action on ACET’s 
previous resolution on this same topic.  ACET emphasized that its efforts to provide 
expert guidance are pointless if CDC does not formally respond or take concrete action.  
To address this concern, Ms. Cole confirmed that she would work with CDC staff to 
determine the status of all of ACET’s outstanding resolutions.  The findings would be 
reported to ACET during the June 2014 meeting.  Several members pointed out that the 
update by the DTBE Corrections Workgroup during the current meeting should serve as 
 
Minutes of the Virtual Meeting 
Advisory Council for the Elimination of Tuberculosis 
March 4, 2014  ♦  Page 32 
a model for CDC to provide a succinct, comprehensive and formal response to all of 
ACET’s resolutions.  Most notably, the workgroup described its activities and progress to 
date on the resolution and categorized each individual action item as “partially initiated,” 
“fully initiated,” “deferred,” or “ongoing.” 
• ACET agreed to maintain a small standing workgroup that would work with CDC staff to 
plan and draft future agendas. 
Topic 4: Future Agenda Items 
ACET proposed several topics to include on future meeting agendas. 
• Status report on ACET’s outstanding resolutions 
• Potential items to include in a TB research agenda 
• DTBE’s organizational structure and future directions under its new leadership 
• In-depth discussion on a strategic plan and concrete action steps for CDC and public 
health departments across the country to jointly identify and treat the large group of TB 
infections that are at risk of progressing to disease.  A status report of CDC’s existing 
recommendations on this topic should be included in this agenda item. 
Closing Session 
Ms. Cole thanked the ACET members for their ongoing commitment, expertise and guidance to 
assist CDC in achieving its national TB elimination goal.  She also thanked the CDC staff for 
preparing comprehensive overviews and informative updates to guide ACET’s discussions.  
ACET commended Ms. Cole on her new role as the ACET Chair.  Several members were 
impressed by her concise and accurate summary of key issues and action items from each 
presentation. 
The remaining two ACET meetings in 2014 would be held on June 9-10, 2014 (an in-person 
meeting in Atlanta, Georgia) and on December 2, 2014 (a webinar). 
With no further discussion or business brought before ACET, Ms. Cole adjourned the virtual 
meeting at 3:21 p.m. on March 4, 2014. 
I hereby certify that to the best of my 
knowledge, the foregoing Minutes of the 
proceedings are accurate and complete. 
___________________    ___________________________________ 
Date  Barbara Cole, RN, MSN, PHN 
Chair, Advisory Council for the 
Elimination of Tuberculosis 
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Attachment 2: Glossary of Acronyms 
3HP Three-month, once-weekly Isoniazid/Rifapentine 
ACA Affordable Care Act 
ACET Advisory Council for the Elimination of Tuberculosis 
AFB Acid-Fast Bacillus 
AHRQ Agency for Healthcare Research and Quality 
ATS American Thoracic Society 
CDC Centers for Disease Control and Prevention 
CoAg Cooperative Agreement 
CSIS Center for Strategic International Studies 
DASH Division of Adolescent and School Health 
DGMQ Division of Global Migration and Quarantine 
DHAP Division of HIV/AIDS Prevention 
DOT Directly-Observed Therapy 
DTBE Division of Tuberculosis Elimination 
DVH Division of Viral Hepatitis 
EMB Ethambutol 
FBP Federal Bureau of Prisons 
FDA U.S. Food and Drug Administration 
FLDs First-Line Drugs 
FOA Funding Opportunity Announcement 
GDF Global Drug Facility 
GTBCO Global TB Coordinating Office 
HCPs Healthcare Providers 
HCV Hepatitis C Virus 
HHS U.S. Department of Health and Human Services 
HPV Human Papillomavirus 
ICE Immigration and Customs Enforcement 
IGRA Interferon Gamma Release Assay 
INH Isoniazid 
IUATLD International Union Against TB and Lung Disease 
KAN Kanamycin 
LTBI Latent TB Infection 
MDR-TB Multidrug-Resistant TB 
MMWR Morbidity and Mortality Weekly Reports 
MOHs Ministries of Health 
 
Minutes of the Virtual Meeting 
Advisory Council for the Elimination of Tuberculosis 
March 4, 2014  ♦  Page 32 
NCHHSTP National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention 
NTCA National Tuberculosis Controllers Association 
PAS Para-Aminosalicylic Acid 
PCSI Program Collaboration and Service Integration 
PrEP Pre-Exposure Prophylaxis 
PZA Pyrazinamide 
RTI Research Triangle Institute 
RTMCCs Regional Training and Medical Consultation Centers 
RVCT Report of Verified Case of Tuberculosis 
SLDs Second-Line Drugs 
TA Technical Assistance 
TAG Treatment Action Group 
TB Tuberculosis 
TB BASICS TB Building and Strengthening Infection Control Strategies 
TST Tuberculin Skin Test 
USAID U.S. Agency for International Development 
USG U.S. Government 
USPHS U.S. Public Health Service 
USPSTF U.S. Preventive Services Task Force 
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